BEAM vs. NTLA

The year-to-date returns for both stocks are quite close, with BEAM having a -29.80% return and NTLA slightly lower at -30.36%.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Beam Therapeutics Inc. (BEAM) and Intellia Therapeutics, Inc. (NTLA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current BEAM Sharpe Ratio is -0.31, which is higher than the NTLA Sharpe Ratio of -0.93. The chart below compares the historical Sharpe Ratios of BEAM and NTLA, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither BEAM nor NTLA has paid dividends to shareholders.

The maximum BEAM drawdown since its inception was -89.12%, smaller than the maximum NTLA drawdown of -96.45%. Use the drawdown chart below to compare losses from any high point for BEAM and NTLA. For additional features, visit the drawdowns tool.

Beam Therapeutics Inc. (BEAM) and Intellia Therapeutics, Inc. (NTLA) have volatilities of 30.42% and 28.98%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Beam Therapeutics Inc. and Intellia Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.